Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753931 | 1.00 | UTS2R (0.43) | UTS2RCNR2SLC6A9SLC6A5CNR1 | |
| SCHEMBL5751509 | 0.91 | UTS2R (0.50) | UTS2RCNR2SLC6A9SLC6A5CNR1 | |
| SCHEMBL5751037 | 0.88 | UTS2R (0.47) | UTS2RCNR2SLC6A9SLC6A5CNR1 | |
| SCHEMBL5751409 | 0.86 | ALDH1A1 (0.48) | UTS2RCNR2SLC6A9PPARGPPARA | |
| SCHEMBL5752379 | 0.86 | ALDH1A1 (0.48) | UTS2RCNR2SLC6A9PPARGPPARA | |
| SCHEMBL5751934 | 0.86 | CNR2 (0.47) | UTS2RCNR2SLC6A9SLC6A5CNR1 | |
| SCHEMBL5753512 | 0.86 | NOS2 (0.47) | UTS2RCNR2SLC6A9SLC6A5CNR1 | |
| SCHEMBL5753521 | 0.86 | NOS2 (0.47) | UTS2RCNR2SLC6A9SLC6A5CNR1 | |
| SCHEMBL5752315 | 0.83 | CNR2 (0.45) | CNR2SLC6A9ALDH1A1LMNA | |
| SCHEMBL5752099 | 0.83 | VNN1 (0.49) | UTS2RSLC6A9PPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | UTS2R 1794/4885CNR2 485/4885SLC6A9 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.